MedTrace Logo

ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors

NCT04645069 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2024-08-14

No results posted yet for this study

Summary

ADG126, ADG126 in Combination with anti-PD1 antibody, and ADG126 in Combination with ADG106 in Patients with Advanced/Metastatic Solid Tumors .

Conditions

  • Advanced/Metastatic Solid Tumors

Interventions

BIOLOGICAL

ADG126 Mono

ADG126 will be administered as an IV infusion over 30-60 minutes ± 15 minutes.

BIOLOGICAL

ADG126-anti PD1

ADG126-toripalimab combination regimen will receive of toripalimab 15 to 30 minutes after the end of the ADG126 infusion

BIOLOGICAL

ADG126-ADG106

ADG126-ADG106 combination regimen will be receive of ADG106 15 to 30 minutes after the end of the ADG126 infusion

Sponsors & Collaborators

  • Adagene Inc

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-15
Primary Completion
2024-01-29
Completion
2024-05-17
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04645069 on ClinicalTrials.gov